Context Therapeutics Inc. (CNTX) — 10-Q Filings

10-Q Filings (6)

• Context Therapeutics Narrows Q3 Loss, R&D Spend Declines — Nov 5, 2025 Risk: high
  Context Therapeutics Inc. (CNTX) reported a net loss of $9,693,237 for the three months ended September 30, 2025, a significant improvement from the $17,459,893
• Context Therapeutics Narrows Q2 Loss Amidst Clinical Pipeline Progress — Aug 6, 2025 Risk: high
  Context Therapeutics Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, as it remains a clinical
• Context Therapeutics Files Q1 2025 10-Q — May 7, 2025 Risk: low
  Context Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The company, focused on pharmaceutical preparations, reported its financial statu
• Context Therapeutics Files Q3 2024 10-Q — Nov 6, 2024 Risk: medium
  Context Therapeutics Inc. filed its 10-Q for the period ending September 30, 2024. The company, focused on pharmaceutical preparations, reported financial data
• Context Therapeutics Files 10-Q for Q2 2024 — Aug 7, 2024 Risk: medium
  Context Therapeutics Inc. filed its 10-Q for the period ending June 30, 2024. The company, incorporated in Delaware, operates in the pharmaceutical preparations
• Context Therapeutics Inc. Files 10-Q for Period Ending March 31, 2024 — May 8, 2024 Risk: low
  Context Therapeutics Inc. (CNTX) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Context Therapeutics Inc. filed a 10-Q report for the period endin

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX